News about "Roche"

Roche and Nurix Partner to Develop BTK Degrader Bexobrutideg

Roche and Nurix Therapeutics have partnered to develop and commercialise bexobrutideg, a potential best-in-class BTK degrader for B-cell malignancies, chronic spontaneous urticaria, and Multiple Sclerosis (MS), aiming to overcome resistance to current BTK inhibitors.

Roche | 09/06/2026 | By News Bureau

Roche Receives CE Mark for Blood-Based Alzheimer's Diagnostic Test

Roche receives CE Mark approval for Elecsys pTau217, a blood-based Alzheimer’s diagnostic test developed with Eli Lilly, aimed at enabling earlier and less invasive detection of amyloid pathology in patients with cognitive decline.

Roche | 13/05/2026 | By News Bureau

Roche Reports Strong Phase III Results for Fenebrutinib in Multiple Sclerosis

Roche’s investigational drug fenebrutinib shows significant reduction in relapse rates and disease activity in multiple sclerosis, offering potential for improved long-term outcomes in patients.

Roche | 23/04/2026 | By News Bureau |  118

Roche Secures FDA Review for Lupus Drug Gazyva

Roche’s Gazyva moves closer to approval for systemic lupus erythematosus after FDA accepts application backed by Phase III trial results showing improved disease control and remission rates.

Roche | 22/04/2026 | By News Bureau

US Food and Drug Administration Reviews Petition to Revoke Approval of Ocrevus for Multiple Sclerosis

The US Food and Drug Administration reviews concerns over Ocrevus, as safety and efficacy questions emerge for its use in primary progressive multiple sclerosis patients.

Roche | 16/04/2026 | By News Bureau |  210

Roche Secures CE Mark for Blood-Based Test to Monitor Multiple Sclerosis

Roche’s Elecsys NfL test receives CE approval, offering a simple blood-based method to detect neuroinflammation in multiple sclerosis, improving monitoring access and supporting more timely, personalised disease management.

Roche | 14/04/2026 | By News Bureau

Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD

Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.

Roche | 25/03/2026 | By News Bureau |  205

Roche Boosts AI Muscle with Nvidia Chip Expansion to Accelerate Drug Discovery

Swiss pharma major Roche has significantly expanded its artificial intelligence (AI) capabilities by deploying thousands of advanced GPUs from Nvidia, marking one of the largest AI infrastructure investments in the pharmaceutical sector.

Roche | 17/03/2026 | By Darshana |  130

Roche Reports Update on PERSEVERA Breast Cancer Trial

Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.

Roche | 09/03/2026 | By News Bureau |  105

Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial

Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.

Roche | 02/03/2026 | By News Bureau |  170